

Technology Appraisal Committee Meeting (Committee D)

Minutes: Unconfirmed

Date and Time: Wednesday 27 July 2016 10:15 – 17:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:

1. Professor Gary McVeigh, Chair	Present for all notes
2. Dr Lindsay Smith, Vice Chair	Present for all notes
3. Dr Andrew Black	Present for all notes
4. Dr Aomesh Bhatt	Present for all notes
5. Dr Matthew Bradley	Present for all notes
6. Ms Tracey Cole	Present for all notes
7. Dr Ian Davidson	Present for all notes
8. Professor Simon Dixon	Present for all notes
9. Mrs Susan Dutton	Present for all notes
10. Dr Alexander Dyker	Present for all notes
11. Mrs Gillian Ells	Present for all notes
12. Dr Susan Griffin	Present for all notes
13. Professor Carol Haigh	Present for all notes
14. Professor John Henderson	Present for all notes
15. Mr Malcolm Oswald	Present for all notes
16. Professor Oluwafemi Oyebode	Present for all notes
17. Dr Mohit Sharma	Present for all notes

In attendance:

Maiwenn Al	Kleijnen Systematic Reviews Ltd (KSR)	Present for notes 01 to 09
Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes 01 to 19
Professor Graham Foster	NHS commissioning expert, nominated by NHS England	Present for notes 01 to 09
Rob Riemsma	Kleijnen Systematic Reviews Ltd (KSR)	Present for notes 01 to 09
Ahmad Abdulla	Research Associate, Liverpool Reviews and Implementation Group (LRIG)	Present for notes 10 to 14
Professor Adrian Bagust	Liverpool Reviews and Implementation Group	Present for notes 10 to 14

Dr Sanjay Bhagani	(LRIG) ERG representative Aberdeen HTA Group	Present for notes 01 to 11
Dr Angela Boland	Associate Director, Liverpool Reviews and Implementation Group (LRIG)	Present for notes 15 to 19
Nasuh Büyükkaramıkl	Health Economic Researcher. Kleijnen Systematic Reviews Ltd (KSR)	Present for notes 01 to 09
Diane Dobson	Patient expert, Pancreatic Cancer UK	Present for notes 01 to 14
Sally Doss	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 01 to 19
Nigel Fleeman	Research Fellow, LRIG	Present for notes 10 to 14
Professor Anna Maria Geretti	Clinical expert, nominated by Gilead	Present for notes 01 to 09
Dr Christian Griffiths	Technical Lead, National Institute for Health and Care Excellence	Present for notes 15 to 19
Rachel Halford	Patient expert, Hepatitis C Trust	Present for notes 01 to 09
Caroline Hall	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 10 to 14
Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes 01 to 19
James Mahon	Liverpool Reviews and Implementation Group (LRIG)	Present for notes 15 to 19
Kelvin Marshall	Patient expert, Liver 4 Life	Present for notes 01 to 09
Dr Mairéad McNamara	Senior lecturer and Honorary Consultant in Medical Oncology Nominated by Shire	Present for notes 10 to 14
Kate Moore	Project Manager, National Institute for Health and Care Excellence	Present for all notes 01 to 19
Dr John Nathan	Patient expert, Pancreatic Cancer UK	Present for notes 10 to 14
Paula O'Grady	National Institute for Health and Care Excellence	Present for all notes 01 to 19
Professor Pieter Postmus	Consultant, nominated by Royal College of Physicians	Present for notes 15 to 19

Malcolm Qualie	Pharmacy Lead, Nominated by NHS England	Present for notes 01 to 14
Aminata Thiam	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 01 to 09

Non-public observers:

Ann Greenwood	NICE observer	Present for notes 01 to 19
Helen Powell	NICE observer	Present for notes 01 to 09
Hiral Shah	NICE observer	Present for notes 01 to 11
Jessica Maloney	NICE observer	Present for notes 01 to 11
Julien Odet	Medical student	Present for notes 01 to 19
Sumeet Gupta	New member of Committee B	Present for notes 01 to 19
Sumithra Maheswaran	New member of committee D	Present for notes 01 to 19

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of elbasvir-grazoprevir for treating chronic hepatitis C. Pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine and Osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer.
2. The Chair informed the Committee of the non-public observers at this meeting: Sumeet Gupta, Sumithra Maheswaran, Jessica Maloney, Helen Powell and Hiral Shah.
3. Apologies were received from Dr Andrew Black, Dr Ian Campbell, Professor Paula Ghaneh, Dr Tim Kinnaird and Dr Paula Parvulescu.

Any other Business

4. None

Appraisal of elbasvir-grazoprevir for treating chronic hepatitis C [ID842]

Part 1 – Open session

5. The Chair welcomed the invited experts: Dr Sanjay Bhagani, Professor Anna Maria Geretti, Rachel Halford and Kelvin Marshall to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Merck Sharp & Dohme to the meeting.
7. The Chair asked all Committee members to declare any relevant interests

- 7.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Aomesh Bhatt, Dr David Bowen, Dr Matthew Bradley, Ms Tracey Cole, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Dr Alexander Dyker, Mrs Gillian Ells, Dr Susan Griffin, Professor John Henderson, Mr Malcolm Oswald, Professor Oluwafemi Oyeboade, Dr Mohit Sharma all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of elbasvir-grazoprevir for treating chronic hepatitis C.
8. The Chair asked all NICE Staff to declare any relevant interests.
- 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of elbasvir-grazoprevir for treating chronic hepatitis C.
9. The Chair asked all other invited guests to declare their relevant interests.
- 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of elbasvir-grazoprevir for treating chronic hepatitis C.
10. The Chair introduced the lead team, Dr Matthew Bradley, Ms Tracey Cole and Professor John Henderson who gave presentations on the clinical effectiveness and cost effectiveness of elbasvir-grazoprevir for treating chronic hepatitis C.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. The Committee continued to discuss the clinical and cost effectiveness of elbasvir-grazoprevir for treating chronic hepatitis C.
- 14.1. The committee decision was based on consensus.

15. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine [ID778]

Part 1 – Open session

16. The Chair welcomed company representatives from Shire to the meeting.
17. The Chair asked all Committee members to declare any relevant interests
 - 17.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Aomesh Bhatt, Dr David Bowen, Dr Matthew Bradley, Ms Tracey Cole, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Dr Alexander Dyker, Mrs Gillian Ells, Dr Susan Griffin, Professor John Henderson, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Mohit Sharma all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.
18. The Chair asked all NICE Staff to declare any relevant interests.
 - 18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.
19. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
20. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
21. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

22. The Committee continued to discuss the clinical and cost effectiveness of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.

- 22.1. The committee decision was based on consensus.
23. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer [ID874]

Part 1 – Open session

24. The Chair welcomed company representatives from AstraZeneca to the meeting.
25. The Chair asked all Committee members to declare any relevant interests
- 25.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Aomesh Bhatt, Dr David Bowen, Dr Matthew Bradley, Ms Tracey Cole, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Dr Alexander Dyker, Mrs Gillian Ells, Dr Susan Griffin, Professor John Henderson, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, Dr Mohit Sharma all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer.
26. The Chair asked all NICE Staff to declare any relevant interests.
- 26.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer.
27. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
28. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
29. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

30. The Committee continued to discuss the clinical and cost effectiveness of osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer.
 - 30.1 The committee decision was based on consensus.
31. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

32. Thursday 25 August 2016, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.